Financial Performance - The total distributable profit as of December 31, 2023, is RMB 235,276,213.60, with the parent company's distributable profit at RMB 213,599,678.39[5]. - The proposed cash dividend is RMB 0.083 per share (before tax), totaling RMB 2,859,350.00 based on a total share capital of 344,500,000 shares[5]. - The net profit attributable to shareholders for the year is RMB 7,925,121.12, with a cash dividend payout ratio of 36.08%[5]. - The company's operating revenue for 2023 was CNY 572.75 million, a decrease of 2.21% compared to CNY 585.68 million in 2022[21]. - The net profit attributable to shareholders for 2023 was a loss of CNY 76.03 million, representing a decline of 88.36% from a profit of CNY 68.07 million in 2022[22]. - The basic earnings per share for 2023 was CNY 0.02, down 90.00% from CNY 0.20 in 2022[23]. - The company's cash flow from operating activities showed a net outflow of CNY 66.88 million, which is an improvement of 63.11% compared to the previous year[25]. - The total assets of the company at the end of 2023 were CNY 5.05 billion, a decrease of 2.13% from CNY 5.16 billion at the end of 2022[22]. - The weighted average return on equity for 2023 was 0.19%, a decrease of 1.41 percentage points from 1.60% in 2022[23]. - The company reported a total of CNY 83.95 million in non-recurring gains for 2023, compared to CNY 80.99 million in 2022[30]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Management Discussion and Analysis" section[4]. - The report includes a forward-looking statement risk disclaimer, indicating that future plans and strategies do not constitute a commitment to investors[7]. - The company is at risk of potential losses if adverse factors affecting its performance continue to worsen, particularly in the pharmaceutical packaging sector[75]. - The company is exposed to financial risks, including a significant reliance on foreign suppliers for raw materials, which may impact production and cost control[79]. - The company faces risks related to large accounts receivable, which amounted to CNY 634.24 million, accounting for 16.66% of current assets[81]. - The company is exposed to risks from military procurement fluctuations and pricing delays, which could impact revenue and performance[82]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[8]. - The board of directors has approved the profit distribution plan, which is subject to shareholder meeting approval[5]. - The company has established a comprehensive internal control system to enhance decision-making and operational efficiency, with a 100% control rate on 39 management system changes during the reporting period[196]. - The company emphasizes ESG practices, integrating environmental and social responsibility into daily operations, and adheres to carbon neutrality goals[198]. - The governance mechanism ensures professional and efficient internal discussions and decision-making processes[200]. - The company focuses on protecting investor rights and interests through transparent governance practices[200]. Research and Development - Research and development expenses accounted for 9.03% of operating revenue, down from 11.34% in the previous year[23]. - The company invested 9.03% of its revenue in R&D, applying for 47 patents in total, including 25 invention patents[37]. - The company has achieved significant technological advancement in the production of pharmaceutical rubber stoppers, establishing a comprehensive formula system and mature production processes, positioning itself at the forefront of the industry both domestically and internationally[52]. - The company is committed to increasing R&D investment to enhance its independent innovation capabilities and aims to establish a robust technology system for key innovations[130]. - The company has established long-term partnerships with various research institutions and universities to enhance its R&D capabilities[72]. Market and Product Development - The company is actively expanding into the pharmaceutical packaging and medical device markets, including non-PVC multi-layer co-extruded films and medical protective clothing[70]. - The company is exploring new directions in mask production, particularly with the development of nano masks, which are expected to become a new trend in medical protective equipment[57]. - The company plans to complete the development of the "Filtering Absorber XX" project by 2024, with a total investment of RMB 1,369.61 million, and has achieved prototype testing[64]. - The company is focused on expanding its market presence in military products while maintaining quality and timely delivery of military supplies[134]. - The company anticipates intensified competition in the military supplies sector as market access barriers are lowered, allowing more enterprises to enter the industry[125]. Operational Efficiency - The company has implemented smart manufacturing in its production processes, achieving a 51% increase in production efficiency and a 20% reduction in operating costs[70]. - The company has established a production capacity for the "Insulin Pen Injector Components," with a total investment of RMB 514.97 million, and is entering the review process in 2024[64]. - The company has completed 59 training projects in 2023, covering various employee groups to improve knowledge structure and business quality[184]. - The company maintains a direct sales model for all products, with no distribution model in place, ensuring control over sales processes[95]. - The company has implemented a performance evaluation mechanism for senior management, linking compensation to market standards and performance contributions[195]. Shareholder Engagement - The company held 4 shareholder meetings during the reporting period, reviewing 17 proposals[140]. - The company actively engaged with investors through various communication channels, enhancing transparency and investor relations[142]. - The company has not issued any new shares or made any changes to the existing shareholding structure during the reporting period[148]. - The company reported a total revenue of 64.48 million CNY for the year, with no changes in shareholding for key executives[147]. - The company has established a remuneration decision-making process that involves shareholder meetings and board reviews[161].

湖北华强科技股份有限公司 2024 年度"提质增效重回报"行动方案 为深入贯彻党中央、国务院决策部署,认真落实中央经济工作会议、中央金 融工作会议精神,根据国务院国资委《关于印发〈提高央企控股上市公司质量工 作方案〉的通知》等相关文件要求,湖北华强科技股份有限公司(以下简称"公 司")积极响应并践行以投资者为本的发展理念,2024年将继续履行强军首责、 聚焦主责主业,强化科技创新驱动,持续提高国防装备质量,提升企业价值,积 极回报全体股东,结合公司实际情况,制定本实施方案。 一、认清形势、坚定信心,坚决贯彻落实中央经济工作会议精神 中央经济工作会议对当前和今后一个时期形势做了深刻分析,对下一步发展 提出了明确要求。会议强调,做好 2024年经济工作,要以习近平新时代中国特 色社会主义思想为指导,全面贯彻落实党的二十大和二十届二中全会精神,坚持 稳中求进工作总基调,完整、准确、全面贯彻新发展理念,加快构建新发展格局, 着力推动高质量发展,全面深化改革开放,推动高水平科技自立自强。会议要求, 2024 年要坚持稳中求进、以进促稳、先立后破,多出有利于稳预期、稳增长、 稳就业的政策,在转方式、调结构、提质量、增效益 ...

2023年半年度报告 公司代码：688151 公司简称：华强科技 湖北华强科技股份有限公司 2023 年半年度报告 ...

证券代码：688151 证券简称：华强科技 公告编号：2024-014 湖北华强科技股份有限公司 第二届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 湖北华强科技股份有限公司（以下简称"公司"）第二届监事会第三次会议 （以下简称"本次会议"）于 2024 年 4 月 25 日在公司会议室以现场方式召开， 本次会议通知已于 2024 年 4 月 15 日以邮件方式送达公司全体监事。本次会议由 监事会主席刘跃东先生主持，会议应出席监事 3 人，实际出席监事 3 人。本次会 议的召集、召开符合《中华人民共和国公司法》等法律法规和《湖北华强科技股 份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： （一）审议通过《2023 年度监事会工作报告》 监事会认为：公司《2023 年度监事会工作报告》真实、准确、完整地体现了 公司监事会 2023 年度工作情况。公司监事会在 2023 年度认真遵守《公司法》、 《公司章程》等法 ...

湖 北 华 强 科 技 股 份 有 限 公 司 内 部 控 制 审 计 报 告 天 职 业 字 [2024]22695 号 目 录 内 部控制审计报告一 -1 " 报告 内部控制审计报告 天职业字[2024]22695 号 湖北华强科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了湖 北华强科技股份有限公司(以下简称"华强科技"或"公司")2023年12月31日的财务报告 内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是华强科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 天职业字[2024]22695 号 [此页无正文] 中国注册会计师 (项目合伙人): 010150 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变 ...

按照中国证券监督管理委员会《关于规范上市公司与企业集团财务公司业务 往来的通知》《上市公司信息披露管理办法》《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》以及《企业集团财务公司管理办法》的要 求，通过查验兵器装备集团财务有限责任公司（以下简称"财务公司"）《金融许 可证》《企业法人营业执照》等证件资料，并审阅财务公司包括资产负债表、利 润表、现金流量表等在内的定期财务报告，湖北华强科技股份有限公司（以下简 称"公司"或"本公司"）对财务公司的经营资质、业务和风险状况进行了评估， 具体情况报告如下： 湖北华强科技股份有限公司 关于对兵器装备集团财务有限责任公司的 风险评估报告 一、财务公司基本情况 （一）业务资质 1．财务公司是经中国银行保险监督管理委员会批准成立的非银行金融机构。 持有中国银行保险监督管理委员会颁发的《金融许可证》，证件号为： L0019H211000001；持有北京市工商行政管理局颁发的《营业执照》，统一社会 信用代码为：911100007109336571。 2．财务公司注册资本 303,300 万元人民币，其中：中国兵器装备集团公司 （以下简称兵器装备集团）出资 ...

关于湖北华强科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1 1、 专项审计报告 2、 附表 委托单位：湖北华强科技股份有限公司 审计单位：天职国际会计师事务所（特殊普通合伙） 联系电话：0717-6347288 2 | | | | | 2023 年度非经营性资金占用及其他关联资金往来情况汇 | | | | | 单位:人民币万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 金占用方名粉 | 用方与上市公 司的关联关 | 市公司核 的会计科目 | 023 年期初 用资金余额 | 23 年度占用累 金额(不含利用 | 023 年度占用 的利息(如有 | 023 年度偿 景计发生金 | 023 年期 用资金余 | 占用形成原 | 与用性 | | 994 BB 大股东及其附属企 | 无 无 | | | | | | | | | 经营性占 经营性占用 | | 总计 | | | | | | | | | | | | 它关联资金往 | 资金往来方名称 | 来方与上市公 的关联关 ...

证券代码：688151 证券简称：华强科技 公告编号：2024-018 单位：元 | | | | 占 2023 年经审计归属 | | --- | --- | --- | --- | | 类别 | 资产名称 | 本期发生额 | 母公司股东净利润的 | | | | | 比例 | | 信用减值损失（损 | 应收账款信用减值损失 | -14,359,647.85 | -181.19% | | 失以"-"填列） | 其他应收款信用减值损失 | -5,749.05 | -0.07% | 1 | 类别 | 资产名称 | 本期发生额 | 占 2023 年经审计归属 | | --- | --- | --- | --- | | | | | 母公司股东净利润的 | | | | | 比例 | | 小计 | | -14,365,396.90 | -181.26% | | 资产减值损失（损 | 存货减值损失 | -11,664,198.76 | -147.18% | | 失以"-"填列） | 小计 | -11,664,198.76 | -147.18% | | 合计（损失以"-"填列） | | -26,029,595.66 | -328 ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 预计2024年度日常关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为湖北华强科技股份有限公司（以下简称"华强科技"或"公司"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐 业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件 的规定，对公司预计 2024 年度日常关联交易的事项进行了认真、审慎的核查， 具体情况如下： 一、日常关联交易的基本情况 （一）日常关联交易履行的审议程序 2024 年 4 月 25 日，公司召开第二届董事会第六次会议，审议通过了《预计 2024 年度日常关联交易的议案》，关联董事唐伦科先生、张亚昌先生、邹晓丽女 士、徐斌先生回避表决，其余非关联董事对该议案一致同意。表决程序符合《公 司法》《证券法》等法律法规以及《公司章程》的有关规定。表决结果：5 票同 意，0 票反对，0 票弃权。 2024 年 4 月 25 日，公司召开第二届监事会第三次会议，审议通过了《预计 ...